Magnets for smart minds Why tech hubs will continue to be important drivers of growth
This article was first published in Adlershof Journal.
Soon, JPT Peptide Technologies GmbH will bid its final farewells to the Centre of Biotechnology and the Environment (ZBU). The biotech company’s rapid growth demands larger facilities and laboratories for its 150 employees and hundreds of machines. “We are currently completing the construction of a new production site spanning over 8,000 square metres,” says managing director Aurélien Claeyssen. “This new site will accommodate more than 220 employees and expand our technological capacities.”
JPT develops and manufactures peptides—small molecules used across a wide array of life science applications. “Peptides can, for instance, be used in the treatment of certain types of cancer, the assessment of the effectiveness of vaccines, or, more recently, treatment of obesity,” explains Claeyssen.
